{"id":283,"date":"2020-03-03T16:42:22","date_gmt":"2020-03-03T07:42:22","guid":{"rendered":"https:\/\/www.ssri.com\/china\/e\/chinanews\/?p=283"},"modified":"2020-03-19T16:48:07","modified_gmt":"2020-03-19T07:48:07","slug":"launch-of-patientsmap-china-2019","status":"publish","type":"post","link":"https:\/\/www.ssri.com\/china\/e\/chinanews\/283","title":{"rendered":"Launch of PatientsMap China 2019"},"content":{"rendered":"<p style=\"text-align: left\">\n<img loading=\"lazy\" decoding=\"async\" class=\"alignnone  wp-image-287\" src=\"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-content\/uploads\/sites\/3\/2020\/03\/Pmap-CN-2019.png\" alt=\"\" width=\"480\" height=\"227\" srcset=\"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-content\/uploads\/sites\/3\/2020\/03\/Pmap-CN-2019.png 781w, https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-content\/uploads\/sites\/3\/2020\/03\/Pmap-CN-2019-300x142.png 300w, https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-content\/uploads\/sites\/3\/2020\/03\/Pmap-CN-2019-768x364.png 768w\" sizes=\"auto, (max-width: 480px) 100vw, 480px\" \/><\/p>\n<p style=\"text-align: left\">On March 3rd, 2020, SSRI and M3 launched the updated version of PatientsMap China<\/p>\n&nbsp;<p style=\"text-align: left\">\n<strong>Introduction to<\/strong><strong>\u00a0PatientsMap:<\/strong><\/p>\n<p style=\"text-align: left\">PatientsMap is a database product which uncovers the types of diseases that various specialists see, and the monthly patient volume for each disease. The data is collected from around 40,000 physicians (from Japan, USA, UK and China) covering approximately 400 diseases\/conditions.\u00a0 PatientsMap data collection is conducted via online in collaboration with M3.<\/p>\n<p style=\"text-align: left\">PatientsMap can also be used as a tool for estimating nationwide patient numbers for various diseases across, not only different specialties, but also by hospital tiers and city tiers. It can help you in analyzing the potential of a new drug and also for targeting the appropriate specialties in terms of market research and\/or for promotional purposes.<\/p>\n<p style=\"text-align: left\">PatientsMap China 2019 data was collected from over 12,000 physicians (approx. 20% increase from 2018 version), covering approximately 380 diseases\/conditions.<\/p>\n<p style=\"text-align: left\">\n<\/p>\n<p style=\"text-align: left\"><strong>Outline of Patient<\/strong><strong>sMap 2019 China:<\/strong><\/p>\n<ol style=\"text-align: left\"><li>Product name: PatientsMap 2019 China<\/li>\n<li>Objective: To understand the treatment condition of various specialties for 357 diseases\/conditions<\/li>\n<li>Methodology: Online survey<\/li>\n<li>Survey region: Nationwide<\/li>\n<li>Sample size: 12,108 physicians from various departments<\/li>\n<li>Fieldwork schedule: 2019 September 6th \u2013 December 5th<\/li>\n<\/ol>\n<p style=\"text-align: left\">\n<\/p>\n<p style=\"text-align: left\">\n<strong>Contents of PatientsMap:<\/strong><\/p>\n<ul style=\"list-style-type: square\"><li style=\"text-align: left\">&gt; Total number of patients that they see (per month)<\/li>\n<li style=\"text-align: left\">&gt; Diseases\/conditions that they see (386 disease types)<\/li>\n<li style=\"text-align: left\">&gt; Number of patients they see\u00a0per each disease\/condition<\/li>\n<li style=\"text-align: left\">&gt; Number of patients in which they prescribe medications for that disease\/condition<\/li>\n<li style=\"text-align: left\">&gt; Diseases in which they wish for new product development<\/li>\n<li style=\"text-align: left\">&gt; Sales rep visitations in the past month (64 manufacturers)<\/li>\n<li style=\"text-align: left\">&gt; Information provision via\u00a0non-face-to-face methods (64 manufacturers)<\/li>\n<li style=\"text-align: left\">&gt; Demographics<\/li>\n<li style=\"text-align: left\">\u00a0 \u00a0 \u00a0- Primary specialty<\/li>\n<li style=\"text-align: left\">\u00a0 \u00a0 \u00a0- Area of specialty\/sub-specialties<\/li>\n<li style=\"text-align: left\">\u00a0 \u00a0 \u00a0- Province and city of the practice<\/li>\n<li style=\"text-align: left\">\u00a0 \u00a0 \u00a0- Hospital type and tier level<\/li>\n<li style=\"text-align: left\">\u00a0 \u00a0 \u00a0- Number of beds at the hospital<\/li>\n<li style=\"text-align: left\">\u00a0 \u00a0 \u00a0- Title<\/li>\n<li style=\"text-align: left\">\u00a0 \u00a0 \u00a0- Age range<\/li>\n<\/ul>\n&nbsp;<p style=\"text-align: left\">For more information on PatientsMap, please contact;\u00a0 <a href=\"mailto:patientsmap@ssri.com\">patientsmap@ssri.com<\/a><\/p>\n<p style=\"text-align: left\">\n<p style=\"text-align: left\">\n","protected":false},"excerpt":{"rendered":"<p>On March 3rd, 2020, SSRI and M3 launched the updated version of PatientsMap China &nbsp; Introduction to\u00a0PatientsMap: PatientsMap is a database product which uncovers the types of diseases that various specialists see, and the monthly patient volume for each disease. The data is collected from around 40,000 physicians (from Japan, USA, UK and China) covering approximately 400 diseases\/conditions.\u00a0 PatientsMap data collection is conducted via online in collaboration with M3. PatientsMap can also be used as a tool for estimating nationwide patient numbers for various diseases across, not only different specialties, but also by hospital tiers and city tiers. It can help you in analyzing the potential of a new drug...  <a class=\"excerpt-read-more\" href=\"https:\/\/www.ssri.com\/china\/e\/chinanews\/283\" title=\"Read Launch of PatientsMap China 2019\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-283","post","type-post","status-publish","format-standard","hentry","category-chinanews"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/posts\/283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/comments?post=283"}],"version-history":[{"count":4,"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/posts\/283\/revisions"}],"predecessor-version":[{"id":289,"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/posts\/283\/revisions\/289"}],"wp:attachment":[{"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/media?parent=283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/categories?post=283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ssri.com\/china\/e\/chinanews\/wp-json\/wp\/v2\/tags?post=283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}